© 2024 Corcept Therapeutics, Incorporated
Featured
Stories
All Stories
‘Constantly stressed out’: A woman’s battle with excess cortisol
Article:
Honoring Ildaura Murillo-Rohde
Article:
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Article:
Navigating Hypercortisolism: Deile’s Story
Article:
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
Press Release: Jun 24, 2024
Celebrating Dr. Neena Schwartz
Article:
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
Press Release: May 28, 2024
What is Hypercortisolism?
Featured Content:
Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer
Publication: March 18, 2024